NCT06535737View on ClinicalTrials.gov

A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions

Hepatocellular Carcinoma Non-resectable

Interventions

DRUG

Cabozantinib

Cabozantinib (Cabometyx) 60, 40 and 20 mg

All Listed Sponsors

collaborator

Mahidol University

OTHER

lead

Chulalongkorn University

OTHER